Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect of Uncut Roux-en-Y Gastrojejunostomy on Quality of Life After Laparoscopic Distal Gastrectomy for Early Gastric Cancer Patients
Brief Summary: The current commonly used for distal gastri cancer in gastrointestinal anastomosis is Roux-en-Y. However, the complications after Roux-en-Y reach an incidence of over 30% which involve nausea, vomiting, and abdominal distension. The underlying mechanism might be the result of interruption of intestine peristalsis. In 2013, Kim reported total laparoscopic uncut Roux-en-Y anastomosis could reduce Roux stasis syndrome incidence by keeping the continuity of jejunum. In September 2014, we carried out this operation in 30 cases in our centre. Our previous results showed that this operation had a low postoperative complication and short hospitalization time, indicating uncut Roux-en-Y anastomosis might be a safe procedure. However, some limitations are noticed. The report from South Korea is a retrospective study and the evaluation of QOL is certain subjective. Here, we aimed to perform the first randomized controlled clinical study on uncut Roux-en-Y anastomosis to improve QOL of patients after laparoscopic distal gastrectomy.


Options:
A: Inclusion Criteria:

* Clinical diagnosis of distal gastric cancer
* underwent laparoscopy-assisted distal gastrectomy

Exclusion Criteria:

* have simultaneously other cancer
* have severe systemic inflammatory disease ,serious illness such as diabetes, chronic lung diseases
* have upper gastrointestinal surgery
* can't bear the gastric tube
* the period is too late or the tumor is too large to carry on a laparoscopy assisted radical distal gastrectomy
B: Inclusion Criteria:

* Endoscopy and biopsy confirmed gastric antrum or angle (from the cardia more than 4cm) of gastric cancer
* tumor stage: I
* There is no experience with chemotherapy, no distant metastasis
* Have their own ability to answer the questionnaire
* There is no mental illness
* Age between 18-70 years old
* Agreed to participate in the experiment and signed informed consent

Exclusion Criteria:

* pregnant or nursing patients
* The combined more serious cardiovascular disease, liver and kidney dysfunction (glutamic-pyruvic transaminase/glutamic oxalacetic transaminase more than three times the upper limit of normal, serum creatinine more than 50% higher than the upper limit of normal), abnormal blood clotting function (mean prothrombin time, activated partial thromboplastin time higher than normal values above the upper limit of 50%), neuropsychiatric disorders
* Patients with active infection
* Have other malignant tumor
* Some reason withdraw subjects, can not enrolled in the study again
C: Inclusion Criteria:

1. pathological diagnosed as the gastric carcinoma, the possibility of removal by the surgeon and imaging physician assessment.
2. no previous history of other malignancies combined.
3. patients have signed informed consent;
4. aged 18 to 80 years old, male or female patients;
5. cardiopulmonary, liver and kidney function was normal, ECOG physical status score of 0 to 1 (see Appendix);
6. the clinician determine the patient does not need emergency surgery;

Exclusion Criteria:

1. pregnant or lactating women;
2. the liver, lung, bone, and other distant metastasis;
3. supraclavicular lymph nodes, pelvic or ovarian species, peritoneal dissemination, etc;
4. a large number of ascites, cachexia;
5. suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension merger, diabetes patients;
6. or mental illness;
7. 4 weeks prior to enrollment participated or are participating in other clinical trials of patients;
8. had undergone surgery, and its influence has not been eliminated in the patient;
9. of the stomach or esophagus history of malignancy, including stromal tumor, sarcoma, lymphoma, carcinoid;
10. patients with active infection (infection causing fever above 38 ℃);
11. patients with poor compliance or researchers consider poor patient compliance;
12. There are other clinical researchers believe that the laboratory the patient should not participate in the trial.
D: Inclusion Criteria:

* 18\<age\<75
* Gastric lesions were diagnosed as gastric adenocarcinoma by endoscopic biopsy
* The preoperative clinical stage is T1-4a,N0-3,M0(According to AJCC- 7th TNM tumor stage)
* It is expected that the results of R0 surgery can be obtained by performing distal gastrectomy and D2 lymph node dissection
* Preoperative ECOG performance status score 0/1
* Nutrition risk screening（NRS2002）
* Preoperative ASA score I-III
* Patient informed consent

Exclusion Criteria:

* Pregnancy or breastfeeding women
* Severe mental illness
* History of upper abdominal surgery
* History of gastric surgery (including ESD/EMR for gastric cancer)
* 3 years of history of other malignant diseases；
* Gastric cancer patients who have undergone neoadjuvant treatment or recommend neoadjuvant treatment
* A history of unstable angina or myocardial infarction within 6 months
* History of cerebral infarction or cerebral hemorrhage within 6 months
* There is a history of sustained systemic corticosteroid treatment within 1 month
* Needs simultaneous surgical treatment of other diseases；
* Gastric cancer complications (bleeding, perforation, obstruction) require emergency surgery
* Pulmonary function test FEV\<1 predicted value 50%

Answer: B